August 2023 in “MPPKI (Media Publikasi Promosi Kesehatan Indonesia) : The Indonesia journal of health promotion” The document's conclusion cannot be provided because the document is not available or cannot be parsed.
August 2022 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” January 2008 in “프로그램북(구 초록집)” 20 citations,
January 2004 in “PubMed” 1 citations,
December 2020 in “The World Journal of Men's Health” 1 citations,
November 2010 in “Anticancer Research” March 2023 in “JAAD case reports” October 2021 in “European urology open science” June 2021 in “European Urology” February 2019 in “DOAJ (DOAJ: Directory of Open Access Journals)” May 2016 in “The Journal of Sexual Medicine” June 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” September 2017 in “ics.org” January 2009 in “프로그램북(구 초록집)” 1 citations,
August 2022 in “Journal of Dermatological Treatment” February 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 339 citations,
February 2014 in “Journal of The American Academy of Dermatology” Most patients with frontal fibrosing alopecia are postmenopausal women, and treatments like finasteride and dutasteride can improve or stabilize the condition.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
110 citations,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
98 citations,
February 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
47 citations,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
46 citations,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
29 citations,
April 2019 in “BMJ. British medical journal” Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
26 citations,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
19 citations,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
18 citations,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
15 citations,
August 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
13 citations,
February 2022 in “JAMA Dermatology” Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.
8 citations,
January 2016 in “Indian Journal of Pharmacology” Finasteride and dutasteride can cause severe, lasting side effects.